Bifunctional shRNA is unneccessarily complicated and the only...

Bifunctional shRNA is unneccessarily complicated and the only company using it is Gradalis, who refused to acknowledge Benitec's ip, overcomplicated it, and, so far, have been unsuccessful in showing significant results in clinical trials.

Shock horror. You have invested in a highly speculative biotech whose drug (like 99 out of 100) didn't turn out to cure an already curable disease.

If a failed drug results in the death of a company, than the vast majority of listed biotechs would not exist today. Benitec is the cheapest (by market cap/cash backing) listed company I can find and is in no immediate danger of it's cash resources running out despite people on this forum continuing to lie about it's current cash committments. Which, by the way, have at least halved now that the TT-034 ball and chain has been removed.